Ebixa Corporate Strategic Brand Plan - Beijing (Shanghai) HuayiNet Translation Company - Chinese Expert Translation Net

1 647 624 9243
bjctn@hotmail.com

Medicine

Ebixa Corporate Strategic Brand Plan

6.1: Ebixa key publications
An outline of the key Ebixa? publications that are commonly used in the Ebixa? promotional materials, is presented on the following pages. These are the publications that best support Ebixa?’s messages and objectives.
Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 2008; 22 (3): 209–221.
Design and methods	382 patients with probable AD. Patients received combination therapy with an acetylcholinesterase inhibitor (AChEI) + Ebixa?, or an AChEI alone, or no treatment with either medication. Long-term study (mean follow-up 2.5 years).
Endpoints	Cognition (Information-Memory-Concentration subscale of the Blessed Dementia Scale, BDS). Function (Weintraub Activities of Daily Living scale).
Results	The combination of Ebixa? + AChEI was superior to treatment with AChEI alone, or no treatment, on both the cognitive and functional assessment scales. The effect size of Ebixa? in combination with AChEI increased with treatment duration.
Remarks	The combination of Ebixa? with AChEI treatment provides superior efficacy in slowing down cognitive and functional decline compared with AChEI treatment alone.
	The benefits of Ebixa? in combination with AChEI increase with time on treatment.
	This is a key study showing that Ebixa? slows clinical progression in AD.

Cummings JL, Schneider E, Tariot PN, Graham SM. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology 2006; 67 (1): 57–63.
Design and methods	Patients already receiving stable doses of donepezil. Exploratory analysis of a 24-week study. Moderate to severe AD.
Endpoints	Behaviour (NPI). Relationship between global, cognitive and functional measures and changes in behaviour.
Results	Patients treated with Ebixa? in combination with donepezil had significantly lower NPI total scores than patients treated with donepezil plus placebo. Ebixa? in combination with donepezil produced significant benefits in the NPI domains of agitation/aggression, eating/appetite, and irritability/lability. Patients who displayed agitation/aggression at baseline showed significant reduction of these symptoms with Ebixa? plus donepezil combination treatment. Patients without agitation/aggression at baseline showed significantly less emergence of this symptom with Ebixa? plus donepezil combination treatment. Caregivers of Ebixa? plus donepezil combination-treated patients registered less agitation-related distress than carers of placebo-treated patients.
Remarks	This study supports the behavioural benefits of Ebixa?. This study supports the effects seen in the Gauthier et al. 2008 publication (see below), discussing the behavioural benefits of Ebixa? based on six RCTs. This study illustrates the clinical relevance of treating behavioural symptoms, showing that this alleviates caregiver distress.